The authors hypothesized that the significant parenchymal and vascular deposits of beta-amyloid seen in the four younger patients with iCJD compared with other patients suffering with prion disease and control subjects from the general population suggests iatrogenic transmission of the beta-amyloid pathology in addition to the CJD agent is a result of the growth hormone treatment they received. The gene discussed is GH1; the disease is prion disease.